BLUE SKY Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration
Realdatenerhebung bei Brolucizumab-Therapie, reine Beobachtungsstudie bei feuchter altersbedingter Makuladegeneration.
- Nummer:
- NCT04543331
- Sponsor:
- Novartis